Literature DB >> 12135278

Short report: absence of protective neutralizng antibodies to West Nile virus in subjects following vaccination with Japanese encephalitis or dengue vaccines.

N Kanesa-Thasan1, J R Putnak, J A Mangiafico, J E Saluzzo, G V Ludwig.   

Abstract

Protection of individuals against West Nile (WN) encephalitis is an emerging concern in the United States and Europe. We investigated whether immunization with licensed inactivated Japanese encephalitis (JE) vaccine or experimental live attenuated dengue vaccines resulted in induction of cross-neutralizing antibodies against WN virus. Protective neutralizing antibody titers to WN virus were not detected in any volunteer despite successful immunization to related flaviviruses. Vaccination against JE or dengue is unlikely to prevent WN virus infection but may still protect against disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12135278     DOI: 10.4269/ajtmh.2002.66.115

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  19 in total

Review 1.  West Nile virus: a growing concern?

Authors:  L Hannah Gould; Erol Fikrig
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

Review 2.  Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex.

Authors:  Mario Lobigs; Michael S Diamond
Journal:  Expert Rev Vaccines       Date:  2012-02       Impact factor: 5.217

3.  A replication-defective Japanese encephalitis virus (JEV) vaccine candidate with NS1 deletion confers dual protection against JEV and West Nile virus in mice.

Authors:  Na Li; Zhe-Rui Zhang; Ya-Nan Zhang; Jing Liu; Cheng-Lin Deng; Pei-Yong Shi; Zhi-Ming Yuan; Han-Qing Ye; Bo Zhang
Journal:  NPJ Vaccines       Date:  2020-08-05       Impact factor: 7.344

Review 4.  West Nile virus meningoencephalitis.

Authors:  Roberta L Debiasi; Kenneth L Tyler
Journal:  Nat Clin Pract Neurol       Date:  2006-05

5.  ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy.

Authors:  Juan Arroyo; Chuck Miller; John Catalan; Gwendolyn A Myers; Marion S Ratterree; Dennis W Trent; Thomas P Monath
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses.

Authors:  Mario Lobigs; Megan Pavy; Roy A Hall; Päivi Lobigs; Peter Cooper; Tomoyoshi Komiya; Hiroko Toriniwa; Nikolai Petrovsky
Journal:  J Gen Virol       Date:  2010-02-03       Impact factor: 3.891

7.  Dengue and West Nile Virus Transmission in Children and Adults in Coastal Kenya.

Authors:  David M Vu; Tamara Banda; Crystal Y Teng; Chelsea Heimbaugh; Eric M Muchiri; Peter L Mungai; Francis M Mutuku; Julie Brichard; Ginny Gildengorin; Erin M Borland; Ann M Powers; Uriel Kitron; Charles H King; A Desiree LaBeaud
Journal:  Am J Trop Med Hyg       Date:  2016-11-07       Impact factor: 2.345

8.  An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody.

Authors:  Nikolai Petrovsky; Maximilian Larena; Venkatraman Siddharthan; Natalie A Prow; Roy A Hall; Mario Lobigs; John Morrey
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

9.  Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus.

Authors:  Mario Lobigs; Maximilian Larena; Mohammed Alsharifi; Eva Lee; Megan Pavy
Journal:  J Virol       Date:  2008-12-24       Impact factor: 5.103

10.  A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates.

Authors:  Xiao-Feng Li; Yong-Qiang Deng; Hui-Qiang Yang; Hui Zhao; Tao Jiang; Xue-Dong Yu; Shi-Hua Li; Qing Ye; Shun-Ya Zhu; Hong-Jiang Wang; Yu Zhang; Jie Ma; Yong-Xin Yu; Zhong-Yu Liu; Yu-Hua Li; E-De Qin; Pei-Yong Shi; Cheng-Feng Qin
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.